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Disseminated herpes simplex virus (HSV) infection may lead to acute liver failure (ALF) and the need for emergency liver
transplantation (LT). The primary aim of this study was to determine the utility of HSV serological testing and HSV DNA testing
by polymerase chain reaction (PCR) in the diagnosis and management of indeterminate, pregnancy-related, and known
HSV-related ALF. Stored sera obtained on study day 1 or 2 from patients enrolled in the United States ALF Study Group with
indeterminate (n  51), pregnancy-related (n  12), and HSV-related (n  4) ALF were screened for HSV DNA by PCR and
serology. While 7 of the indeterminate and pregnant patients had positive anti-HSV immunoglobulin M, none had detectable
HSV DNA. The 4 known HSV cases all had high-titer HSV DNA on presentation (range: 3.5 to 36  108 copies/mL). Two HSV
patients underwent LT but developed posttransplant extrahepatic HSV infection despite suppression of HSV DNA with
acyclovir treatment, and one of them eventually died. The 2 other fulminant HSV patients died within 48 hours of presentation.
In conclusion, serum HSV DNA indicative of occult HSV infection was not detected in 51 indeterminate and 12 pregnancy-
related ALF patients. The 4 patients with known HSV-related ALF all had high HSV DNA levels at presentation, and despite
the rapid use of antiviral therapy and emergency LT, substantial morbidity and mortality were encountered, highlighting the
poor prognosis with severe disseminated HSV infection. Liver Transpl 14:1498-1504, 2008. © 2008 AASLD.
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Herpes simplex virus (HSV) hepatitis is an uncommon
cause of acute liver failure (ALF) and is usually not
identified until after liver transplantation (LT) or death.
HSV-associated ALF typically occurs as reactivation in
pregnancy or with immunosuppression, although dis-
ease in immunocompetent patients has been reported.
Of great concern is the fact that only a fraction of cases
are diagnosed soon after presentation, and this results
in a high rate of multiorgan involvement and death.1-3
Success with transplantation has been reported,
mostly in neonates and children, although the mortal-
ity is high in adult recipients.3-11
Currently, 17% of adult ALF patients are considered
to have indeterminate etiology.12 Prior studies have
failed to demonstrate an identifiable, causal viral infec-
tion in indeterminate ALF.13-15 Some authors have sug-
gested that occult HSV infection may account for cases
of pregnancy-related or indeterminate ALF and that
polymerase chain reaction (PCR) for HSV DNA should
be performed on presentation.16,17 However, it is un-
known whether PCR testing is more sensitive and spe-
cific than serological assays for detecting HSV as a
cause of ALF or is useful as a quantitative measure in
the management of patients with known HSV ALF. The
aim of our study was to search for cases of occult HSV
hepatitis in an indeterminate and pregnancy-related
ALF group (US ALF registry), as measured by HSV PCR,
and determine the diagnostic utility of HSV PCR com-
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pared to standard serological assays in this population.
In addition, we set out to determine the utility of serial
quantitative HSV PCR assays in relation to outcomes of
patients with known HSV ALF before and after LT.
PATIENTS AND METHODS
Acute Liver Failure Study Group (ALFSG)
Subjects
The ALFSG is a 24-center consortium funded by the
National Institute of Diabetes and Digestive and Kidney
Diseases to determine the etiology, clinical features,
and outcomes of adult patients with ALF.12 Enrollment
requires a written informed consent document ap-
proved by the local institutional review board and
signed by the patient’s next of kin. The study protocol
conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki as reflected in a priori approval by the
institution’s human research committee. All data are
collected at the clinical sites and sent to the University
of Texas Southwestern Medical Center for central re-
view and analysis.
The ALFSG database (n  1033) was searched for all
patients with ALF due to indeterminate causes, preg-
nancy, and HSV. ALF was defined as the onset of co-
agulopathy and encephalopathy within 26 weeks of ill-
ness onset in a patient without preexisting liver
disease. An indeterminate ALF case was defined as a
patient with no identifiable cause of ALF after exclusion
of known infectious, metabolic, immune, malignant,
and vascular etiologies of ALF at the local site using
standard serological, radiological, and histological cri-
teria. Day 1 or 2 stored sera from all 12 ALFSG patients
with pregnancy-related ALF (6 were presumed to have
an acute fatty liver, and 6 were presumed to have
HELLP syndrome) and from 51 randomly selected inde-
terminate ALF patients (from the 152 indeterminate
ALFSG patients overall) were used for testing. All of the
identified HSV ALF (n  4) cases had available daily
serum specimens assayed for HSV DNA with quantita-
tive PCR until the time point of death or LT. Any avail-
able quantitative HSV DNA levels post-transplant were
recorded, if they were performed by the centers. Case
forms were reviewed to determine the clinical presenta-
tion, diagnosis, management, and outcomes of ALF.
The explanted liver histology of the PCR-negative, im-
munoglobulin M (IgM)–positive patients was reviewed
for any evidence of HSV infection.
Testing Procedures
Pretransplant qualitative and quantitative HSV DNA by
PCR (HSV-1 and HSV-2) by TaqMan Assay was mea-
sured at the University of Alabama at Birmingham with
the referenced techniques.18-20 Viral DNA was ex-
tracted from 200 L of serum with the Qiagen BioRobot
EZ1 and blood reagent cartridge. An initial volume of
200 L was extracted and eluted in 200 L of water.
Type-common HSV polymerase TaqMan primers and
probe were selected from type-common regions of the
HSV polymerase gene using Primer Express software
(Applied Biosystems, Foster City, CA). The forward
primer was ACC GCC GAA CTG AGC AGA C, the reverse
primer was TGA GCT TGT AAT ACA CCG TCA GGT, and
the probe was 6FAM-CGC GTA CAC CAA CAA GCG CCT
G-TAMRA. The assay conditions were optimized in an
ABI 7300 SDS (Applied Biosystems, Foster City, CA).
Samples were run in triplicate reactions containing 5
L of target in a final volume of 25 L containing 1 
TaqMan universal master mix and 900 nM of each
primer and 200 nM probe. Thermal cycling was per-
formed with an initial step of 50°C for 2 minutes and
95°C for 10 minutes followed by 40 cycles of denatur-
ation at 95°C for 15 seconds and a combined annealing-
extension step at 60°C for 1 minute. Fluorescence data
were collected during each annealing-extension step
and analyzed with ABI-Prism SDS software version
1.2.3. A plasmid containing HSV DNA polymerase was
used to construct the standard curve. A linear 5-point
standard curve and an NTC (no target control) were run
with each plate. The standard curve ranged from 50 to
5  105 copies/5 L and resulted in Ct values of 36.7 to
22.4 respectively. The lower limit of detection for the
qualitative assay was between 1 and 5 copies/reaction.
Posttransplant quantitative HSV DNA by PCR for pa-
tients 3 and 4 was performed at ViraCor Laboratories
(Lee’s Summit, MO); as such, the values are not equally
comparable to the pretransplant assays performed at
the University of Alabama at Birmingham.
All sera were tested at the University of Texas South-
western Medical Center for type-specific HSV-1 and
HSV-2 antibody by an enzyme-linked immunosorbent
assay, the Captia-type specific immunoglobulin G test,
using antigens and reagents manufactured by Trinity
Biotech (United States). All sera were tested for IgM
indirect fluorescent antibody against HSV-1 and HSV-2
after serum absorption with goat anti-human immuno-
globulin G and a reaction with infected cells and an
anti-human IgM fluoresceinated conjugate.21 The HSV
antigens were obtained from Hemagen Diagnostics, Inc.
(Columbia, MD).
RESULTS
Screening of ALF Groups for HSV
The demographics and clinical presentation of the in-
determinate and pregnancy ALF groups are described
in Table 1. None of the 51 patients with indeterminate
ALF or any of the 12 women with pregnancy-related
ALF had detectable serum HSV DNA by qualitative PCR.
However, 6 of the indeterminate ALF patients and 1 of
the pregnancy ALF patients had positive anti-HSV-1 or
anti-HSV-2 IgM (all 1:20; PCR-negative), while only 2 of
the 4 with known HSV had positive anti-HSV-1 or anti-
HSV-2 IgM (patient 3, 1:80, and patient 4, 1:20,480;
Tables 1 and 2). None of the PCR-negative, IgM-positive
patients had evidence of HSV infection on histological
review of the liver explants.
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Evaluation of Known HSV ALF Patients
All 4 known HSV ALF patients had high circulating
titers of HSV DNA on presentation (Table 2). Patient 1
was a 28-year-old Caucasian female with ulcerative co-
litis on chronic prednisone therapy (20 mg/day) who
presented with abdominal pain and fever without rash
in the 8 days prior to the onset of ALF. Intravenous (IV)
acyclovir therapy (500 mg, 10 mg/kg) was administered
empirically, but the patient died 1 day after admission.
Autopsy revealed massive hepatic necrosis and hemor-
rhage with HSV viral inclusions.
Patient 2 was a 39-year-old Caucasian female with
asthma (no corticosteroids) who presented with abdom-
inal pain, fever, and painful swallowing over 20 days
before the onset of ALF. Acyclovir was not administered.
The patient died 2 days after admission. Autopsy re-
vealed HSV esophagitis and hepatitis with coagulative
necrosis.
Patient 3 is a 58-year-old Caucasian male with
asthma (no corticosteroids) who developed fever and a
vesicular rash in the 8 days prior to ALF. Liver biopsy
showed hepatic necrosis and intranuclear inclusions
consistent with HSV infection. The patient was treated
with IV acyclovir (10 mg/kg three times a day; Fig. 1)
and received a LT 6 days after admission. Initial immu-
nosuppression included tacrolimus, mycophenolate
mofetil (MMF), and 3 days of corticosteroids. IV ganci-
clovir prophylaxis (5 mg/kg once a day) was given after
LT until HSV esophagitis developed on day 36 (HSV
PCR–negative on day 23). MMF was discontinued, and
IV acyclovir was resumed for 10 days. Except for day
23, no other PCR was performed after LT. Post-LT com-
plications included biliary leak and stricture, pneumo-
nia, renal failure, and Aspergillus fumigatus osteomy-
elitis. After 2 years, the patient has not developed
recurrence of HSV on maintenance valacyclovir (500
mg once a day).
Patient 4 was a healthy 44-year-old Caucasian fe-
male who presented with a vesicular eruption and
fever 10 days prior to ALF. Liver biopsy revealed HSV
hepatitis. IV acyclovir (10 mg/kg three times a day)
was administered (Fig. 1), and combined liver/kidney
transplantation was performed 7 days later. Initial
immunosuppression included tacrolimus, MMF, and
corticosteroids. IV acyclovir was continued for 20
days, the patient was switched to IV ganciclovir (5
mg/kg once a day) for 10 days, and then acyclovir was
resumed when a vesicular rash occurred on day 30.
Prednisone and MMF were discontinued. HSV PCR
did not become undetectable until long after LT (Fig.
2). Postoperative complications included Candida
fungemia, Staphylococcus aureus and Enterococcus
faecium bacteremia, biliary stricture, and prolonged
ventilation. While on maintenance valacyclovir, the
patient developed an acyclovir-resistant HSV rash
(negative serum PCR) on day 250. Foscarnet was ad-
ministered, but the patient expired on day 365 with
no obvious HSV disease or viremia. Autopsy was de-
clined by the family.
DISCUSSION
We focused on the utility of screening blood samples for
evidence of occult HSV infection with a highly sensitive
qualitative PCR assay. Our results support previous
findings that HSV is an unlikely culprit in indetermi-
nate and pregnancy ALF.22,23 For the 4 ALFSG patients
with known HSV, quantitative HSV DNA on presenta-
TABLE 1. Demographics, Clinical Presentation, and HSV Testing of Indeterminate and Pregnancy ALF Groups
Indeterminate ALF (n  51) Pregnancy ALF (n  12)
Age (years) 39.3  16.2 29.9  3.7
Sex: female 24 (47.6%) 12 (100%)
Race: white 36 (70.6%) 7 (58.3%)
Fever 17 (33.3%) 1 (8.3%)
Rash* 9 (17.6%) 1 (8.3%)
Symptom onset to admission (days) 17.2  17.6 1.6  0.7
ALT (U/L) 2079  2711 660  2250
Bilirubin (mg/dL) 20.8  13.1 16.4  23.7
INR 3.3  2.1 1.8  0.4
HSV-1 IgM (1:20) 5 (9.8%) 1 (8.3%)
HSV-2 IgM (1:20) 1 (1.9%) 0 (0%)
HSV-1 IgG (1:20) 41 (80.4%) 11 (91.6%)
HSV-2 IgG (1:20) 23 (45.1%) 6 (50%)
HSV PCR 0 (0%) 0 (0%)
Liver transplant 19 (37.3%) 1/12 (8.3%)
Overall survival 31 (60.8%) 6 (50%)
NOTE: Values were recorded at the time of initial hospital presentation and are expressed as means  standard deviation or
percentages.
Abbreviations: ALF, acute liver failure; ALT, alanine aminotransferase; HSV, herpes simplex virus; IgG, immunoglobulin G;
IgM, immunoglobulin M; INR, international normalized ratio; PCR, polymerase chain reaction.
*The appearance and distribution of rash are not described in the case report forms.
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tion was uniformly high. The 2 patients who underwent
LT had experienced a preoperative decline in HSV DNA
with acyclovir. While hepatic recurrence of HSV after LT
was not seen in either, the hospital courses were com-
plicated by extrahepatic HSV infection and numerous
complications, despite a significant reduction in HSV
DNA immediately after hepatectomy and eventual
clearance of viremia. While the data are limited, these
findings suggest that a decline in quantitative HSV DNA
may not correlate with a reduction in posttransplant
extrahepatic HSV or other morbidity.
Interestingly, for 7 of the 63 pregnant/indeterminate
negative PCR patients, anti-HSV-1 or anti-HSV-2 IgM
was detectable at a titer of 1:20, likely representing
false positivity, persistent low-level IgM antibody after
prior infection, or mild serological reactivation in these
acutely ill patients, which can be seen with other her-
pesviruses. A positive serology without viremia would
be highly unlikely to represent actual infection in the
vascularized organs where high-titer viremia is univer-
sal. In support of this, a review of available liver tissue
from these 7 subjects failed to demonstrate evidence of
intranuclear inclusions. In contrast, 2 of the 4 patients
with known HSV infection had negative anti-HSV IgM
levels, which reflected either the inaccuracy of serolog-
ical testing or the fact that the patients were too ill or too
early in the course of infection to manufacture IgM.
However, the other 2 HSV patients had higher titers of
IgM (1:80, 1:20,480). These data highlight concerns
regarding the diagnostic capability of serological testing
for HSV and emphasize the importance of PCR as the
definitive confirmatory test.
When the 2 known HSV cases presented for LT eval-
uation, there was concern that active viremia might be
associated with adverse post-LT outcomes, particularly
recurrent HSV. However, the viral kinetics of HSV have
not been studied in ALF, and the available data suggest
that recurrent HSV hepatitis is rare after LT.3-5,7-11 The
2 patients did not have recurrent hepatitis despite the
presence of viral replication at the time of transplanta-
tion. Merely removing the infected liver with transplan-
tation dramatically reduced the HSV viral load, and this
likely reflected the fact that the liver, being a highly
vascularized organ, was a significant reservoir for HSV.
The viral load of one of the patients did not become
undetectable until 3 months after LT, while the other
cleared more quickly. Interestingly, extrahepatic HSV
disease occurred in both despite declining or undetect-
able HSV DNA. While our data are limited to these
patients, they provide the first insight into the viral
kinetics and associated outcomes of HSV ALF.
The outcomes of the 2 transplanted patients in this
study do not settle the controversy of whether LT for
HSV should be performed in adults. Only 11 adult pa-
tients (9 in the literature and 2 from this report) with
HSV ALF have been reported to have undergone LT; 6
(55%) died post-transplant (the deaths were often not
directly related to recurrent HSV), and most had signif-
icant morbidity.3,5,8-11 It is uncertain if the high mor-
bidity and mortality after LT were due to indirect effects
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illness before and after LT or undiagnosed immunode-
ficiency states that predisposed these patients to HSV
ALF.
Several important limitations of our study require
consideration. First, we screened a randomly selected
subgroup of the indeterminate ALFSG patients for HSV
in order to determine if this initial investigation war-
ranted testing of the entire cohort. Because HSV DNA
was not detected in the serum of any of the 51 indeter-
minate ALF patients, further screening of the remaining
101 indeterminate patients was not undertaken. How-
ever, since the presenting clinical features, demograph-
ics, and outcomes of the randomly selected indetermi-
nate patients were similar to those of the untested
indeterminate patients (data not shown), the subgroup
of tested patients appears to be representative of the
Figure 1. Herpes simplex virus polymerase chain reaction levels during antiviral therapy prior to liver transplantation (patients
3 and 4). Abbreviations: ALF, acute liver failure; IV, intravenous; LT, liver transplantation; LKT, liver-kidney transplantation.
Figure 2. Herpes simplex virus polymerase chain reaction levels during antiviral therapy after liver transplantation (patient 4).
Abbreviations: IV, intravenous; OLT, orthotopic liver transplantation; PO, per os.
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overall indeterminate group. While it is theoretically
possible that HSV DNA could have been detected in 1 or
more of the unscreened patients, our data are consis-
tent with other studies and suggest that HSV infection
is not only an exceedingly uncommon cause of ALF in
general (4 of 1033 consecutive adult patients) but also
unlikely to account for a significant percentage of inde-
terminate ALF cases.22,23 For the known HSV cases,
our serial quantitative PCR analysis was limited by the
small number of patients with HSV ALF in this large
database. Only 2 patients survived long enough to have
daily pre-LT sera available for serial PCR analysis, and
only 1 had serial PCRs performed after LT. The timing of
PCR monitoring was not predetermined and was there-
fore not uniform. Therefore, our understanding of the
viral kinetics still remains limited, and further studies
are needed.
In summary, the detection of HSV DNA by PCR ap-
peared to be more discriminating than serological test-
ing for diagnosing or excluding HSV as a cause of ALF.
Unsuspected HSV infection was not identified in any of
the indeterminate/pregnant ALF patients selected. On
the basis of the small number of known HSV ALF cases
in our study, firm conclusions cannot be made regard-
ing the usefulness of quantitative PCR measurement
before and after LT. However, all HSV hepatitis cases
had high DNA levels, supporting the use of HSV PCR as
a screening test for indeterminate ALF to formulate a
rapid management plan versus other inaccurate and
invasive tests, such as serology and liver biopsy. Given
the poor outcomes of LT for HSV ALF, prospective data
are needed to determine if quantitative HSV DNA test-
ing is useful in predicting morbidity and mortality after
LT and in determining the optimal type and length of
antiviral regimen to use post-transplant.
ACKNOWLEDGMENTS
The members and institutions participating in the US
Acute Liver Failure Study Group are as follows: W.M.
Lee, M.D. (principal investigator), Julie Polson, M.D.,
and Carla Pezzia, University of Texas Southwestern,
Dallas, TX; Anne Larson, M.D., University of Washing-
ton, Seattle, WA; Timothy Davern, M.D., University of
California, San Francisco, CA; Paul Martin, M.D.,
Mount Sinai School of Medicine, New York, NY; Timothy
McCashland, M.D., University of Nebraska, Omaha,
NE; J. Eileen Hay, M.D., Mayo Clinic, Rochester, MN;
Natalie Murray, M.D., Baylor University Medical Cen-
ter, Fort Worth, TX; A. Obaid S. Shaikh, M.D., Univer-
sity of Pittsburgh, Pittsburgh, PA; Andres Blei, M.D.,
Northwestern University, Chicago, IL; Atif Zaman,
M.D., University of Oregon, Portland, OR; Steven Han,
M.D., University of California, Los Angeles, CA; Robert
Fontana, M.D., University of Michigan, Ann Arbor, MI;
Brendan McGuire, M.D., University of Alabama, Bir-
mingham, AL; Ray Chung, M.D., Massachusetts Gen-
eral Hospital, Boston, MA; Alastair Smith, M.B., Ch.B.,
Duke University Medical Center, Durham, NC; Michael
Schilsky, M.D., Cornell/Columbia University, New
York, NY; Adrian Reuben, M.B.B.S., Medical University
of South Carolina, Charleston, SC; Santiago Munoz,
M.D., Albert Einstein Medical Center, Philadelphia, PA;
Rajender Reddy, M.D., University of Pennsylvania, Phil-
adelphia, PA; R. Todd Stravitz, M.D., Virginia Common-
wealth University, Richmond, VA; Lorenzo Rossaro,
M.D., University of California at Davis, Sacramento,
CA; Raj Satyanarayana, M.D., Mayo Clinic, Jackson-
ville, FL; and Tarek Hassanein, M.D., University of Cal-
ifornia, San Diego, CA.
The US Acute Liver Failure Study Group is funded by
National Institutes of Health grant U-01 DK58369. Ad-
ditional funding has been provided by the Stephen B.
Tips Memorial Fund of Northwestern Memorial Hospital
and the Jeanne Roberts Fund of the University of Texas
Southwestern Medical Foundation.
REFERENCES
1. Flewett T, Parker RG, Philip WM. Acute hepatitis due to
herpes simplex in an adult. J Clin Pathol 1969;22:60-66.
2. Kaufman B, Gandhi SA, Louie E. Herpes simplex virus:
case report and review. Clin Inf Dis 1997;24:334-338.
3. Ichai P, Roque Afonso AM, Sebagh M, Gonzalez ME, Codés
L, Azoulay D, et al. Herpes simplex virus-associated acute
liver failure: a difficult diagnosis with a poor prognosis.
Liver Transpl 2005;11:1550-1555.
4. Egawa H, Inomata Y, Nakayama S, Matsui A, Yamabe H,
Uemoto S, et al. Fulminant hepatic failure secondary to
herpes simplex virus infection in a neonate: a case report
of successful treatment with liver transplantation and
perioperative acyclovir. Liver Transpl Surg 1998;4:513-
515.
5. Shanley CJ, Braun DK, Brown K, Turcotte JG, Greenson
JK, Beals TF, et al. Fulminant hepatic failure secondary to
herpes simplex virus hepatitis. Successful outcome after
orthotopic liver transplantation. Transplantation 1995;59:
145-149.
6. Twagira M, Hadzic N, Smith M, Ramaswamy M, Verma A,
Dhawan A, et al. Disseminated neonatal herpes simplex
virus (HSV) type 2 infection diagnosed by HSV DNA detec-
tion in blood and successfully managed by LT. Eur J Pe-
diatr 2004;163:166-169.
7. Longerich T, Eisenbach C, Penzel R, Kremer T, Flechten-
macher C, Helmke B, et al. Recurrent herpes simplex virus
hepatitis after liver retransplantation despite acyclovir
therapy. Liver Transpl 2005;11:1289-1294.
8. Montalbano M, Slapak-Green GI, Neff GW. Fulminant he-
patic failure from herpes simplex virus: post liver trans-
plantation acyclovir therapy and literature review. Trans-
plant Proc 2005;37:4393-4396.
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